Enanta Pharma (ENTA) reported Q4 EPS of ($1.27), $0.02 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $20.32 million versus the consensus estimate of $22.87 million.
Enanta Pharma (ENTA) reported Q4 EPS of ($1.27), $0.02 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $20.32 million versus the consensus estimate of $22.87 million.